*Non-GCs Drug-Induced Osteoporosis DOI: http://dx.doi.org/10.5772/intechopen.108296*

[77] Kannel WB. Risk factors in hypertension. Journal of Cardiovascular Pharmacology. 1989;**13**(Suppl 1):S4-S10. DOI: 10.1097/00005344-198900131- 00003 PMID 2468976

[78] MacGregor GA, Cappuccio FP. The kidney and essential hypertension: A link to osteoporosis? Journal of Hypertension. 1993;**11**(8):781-785. DOI: 10.1097/ 00004872-199308000-00003 PMID 8228200

[79] Gadallah M, Massry SG, Bigazzi R, Horst RL, Eggena P, Campese VM. Intestinal absorption of calcium and calcium metabolism in patients with essential hypertension and normal renal function. American Journal of Hypertension. 1991;**4**(5 Pt 1):404-409. DOI: 10.1093/ajh/4.5.404, PMID 2069773

[80] Young EW, Morris CD, McCarron DA. Urinary calcium excretion in essential hypertension. Journal of Laboratory and Clinical Medicine. 1992;**120**(4):624-632 PMID 1402338

[81] Cappuccio FP, Meilahn E, Zmuda JM, Cauley JA. High blood pressure and bone-mineral loss in elderly whitewomen: a prospective study. Lancet. 1999;**354**(9183):971-975. DOI: 10.1016/ s0140-6736(99)01437-3 PMID 10501357

[82] Tsuda K, Nishio I, Masuyama Y. Bone mineral density in women with essential hypertension. American Journal of Hypertension. 2001;**14**(704- 707):704-707. DOI: 10.1016/s0895- 7061(01)01303-6 PMID 11465657

[83] Vestergaard P, Rejnmark L, Mosekilde L. Hypertension is a risk factor for fractures. Calcified Tissue International. 2009;**84**(2):103-111. DOI: 10.1007/s00223-008-9198-2 PMID 19067019

[84] Sennerby U, Melhus H, Gedeborg R, Byberg L, Garmo H, Ahlbom A, et al.

Cardiovascular diseases and risk of hip fracture. Journal of the American Medical Association. 2009;**302**(15):1666- 1673. DOI: 10.1001/jama.2009.1463 PMID 19843901

[85] Pérez-Castrillón JL, Martín-Escudero JC, Alvarez Manzanares P, Cortés Sancho R, Iglesias Zamora S, García AM. Hypertension as a risk factor for hip fracture. American Journal of Hypertension. 2005;**18**(1):146-147. DOI: 10.1016/j.amjhyper.2004.08.016 PMID 15691630

[86] McCarron DA, Pingree PA, Rubin RJ, Gaucher SM, Molitch M, Krutzik S. Enhanced parathyroid function in essential hypertension:A homeostatic response to a urinary calcium leak. Hypertension. 1980;**2**(2):162-168. DOI: 10.1161/01.hyp.2.2.162 PMID 7380520

[87] Strazzullo P, Nunziata V, Cirillo M, Giannattasio R, Ferrara LA, Mattioli PL, et al. Abnormalities of calcium metabolism in essential hypertension. Clinical Science (London, England). 1983;**65**(2):137-141. DOI: 10.1042/cs0650137 PMID 6305548

[88] Cappuccio FP, Kalaitzidis R, Duneclift S, Eastwood JB. Unravelling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism. Journal of Nephrology. 2000;**13**(3):169-177 PMID 10928292

[89] Rosano C, Longstreth WT Jr, Boudreau R, Taylor CA, Du Y, Kuller LH, et al. High blood pressure accelerates gait slowing in well-functioning older adults over 18-years of follow-up. Journal of the American Geriatrics Society. 2011;**59**(3):390-397. DOI: 10.1111/j.1532- 5415.2010.03282.x PMID 21391929

[90] Bergland A, Jarnlo GB, Laake K. Predictors of falls in the elderly by location. Aging Clinical and Experimental Research. 2003;**15**(1):43- 50. DOI: 10.1007/BF03324479 PMID 12841418

[91] Schweiger JU, Schweiger U, Hüppe M, Kahl KG, Greggersen W, Fassbinder E. Bone density and depressive disorder: A metaanalysis. Brain and Behavior: A Cognitive Neuroscience Perspective. 2016;**6**(8):e00489. DOI: 10.1002/ brb3.489 PMID 27547495

[92] Yirmiya R, Bab I. Major depression is a risk factor for low bone mineral density: A meta-analysis. Biological Psychiatry. 2009;**66**(5):423-432

[93] Klibanski A, Adams-Campbelll L, Bassford T, Blair SN, Boden SD, Dickersin K, et al. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. Journal of the American Medical Association. 2001;**285**(6):785-795. DOI: 10.1001/jama.285.6.785 PMID 11176917. Available from: http://consensus.nih.gov

[94] Weaver CM, Gordon CM, Janz KF, Kalkwarf HJ, Lappe JM, Lewis R, et al. Osteoporosis Foundation's position statement on peak bone mass development and lifestyle factors:A systematic review and implementation recommendations. Osteoporosis International. 2016;**27**(4):1281-1386. DOI: 10.1007/ s00198-015-3440-3 PMID 26856587

[95] Cizza G, Primma S, Csako G. Depression as a risk factor for osteoporosis. Trends in Endocrinology and Metabolism. 2009, 2009;**20**(8):367- 373. DOI: 10.1016/j.tem.2009.05.003 PMID 19747841

[96] Haney EM, Warden SJ, Bliziotes MM. Effects of selective serotonin reuptake inhibitors on bone health in adults: Time for recommendations about screening,

prevention and management? Bone .Research support, N.I.H., extramural review. 2010;**46**(1):13-17

[97] Ortuño MJ, Robinson ST, Subramanyam P, Paone R, Huang YY, Guo XE, et al. Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect. Nature Medicine. 2016;**22**(10):1170e9. DOI: 10.1038/ nm.4166 PMID 27595322

[98] Rawson KS, Dixon D, Civitelli R, Peterson TR, Mulsant BH, Reynolds CF 3rd, et al. Bone turnover with venlafaxine treatment in older adults with depression. Journal of the American Geriatrics Society. 2017;**65**(9):2057-2063. DOI: 10.1111/jgs.14936 PMID 28555718

[99] Warden SJ, Robling AG, Haney EM, Turner CH, Bliziotes MM. The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5). Bone. 2010;**46**(1):4-12. DOI: 10.1016/j. bone.2009.06.029 PMID 19591966

[100] Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: A sys thematic review and metaanalysis: I. Psychotropic drugs. Journal of the American Geriatrics Society. 1999;**47**:30.e9

[101] Rabenda V, Nicolet D, Beaudart C, Bruyère O, Reginster JY. Relationship between use of antidepressants and risk of fractures: A metaanalysis. Osteoporosis International. 2013;**24**(1):121-137. DOI: 10.1007/s00198- 012-2015-9 PMID 22638709

[102] Rauma PH, Pasco JA, Berk M, Stuart AL, Koivumaa-Honkanen H, Honkanen RJ, et al. The association between major depressive disorder, use of antidepressants and bone

*Non-GCs Drug-Induced Osteoporosis DOI: http://dx.doi.org/10.5772/intechopen.108296*

mineral density (BMD) in men. Journal of Musculoskeletal and Neuronal Interactions. 2015;**15**:177.e85

[103] Hung SC, Lin CH, Hung HC, Lin CL, Lai SW. Use of selective serotonin reuptake inhibitors and risk of hip fracture in the elderly: A casecontrol study in Taiwan. Journal of the American Medical Directors Association. 2017;**18**(4):350-354. DOI: 10.1016/j. jamda.2016.12.003 PMID 28159466

[104] Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998;**351**(9112):1303-1307. DOI: 10.1016/ s0140-6736(97)09528-7 PMID 9643791

[105] Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporosis International. 2006;**17**(6):807-816. DOI: 10.1007/ s00198-005-0065-y PMID 16520889

[106] Vestergaard P, Rejnmark L, Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcified Tissue International. 2008;**82**(2):92-101. DOI: 10.1007/s00223-007-9099-9 PMID 18219438

[107] Gagne JJ, Patrick AR, Mogun H, Solomon DH. Antidepressants and fracture risk in older adults: A comparative safety analysis. Clinical Pharmacology and Therapeutics. 2011;**89**(6):880-887. DOI: 10.1038/ clpt.2011.54 PMID 21508938

[108] van den Brand MW, Pouwels S, Samson MM, van Staa TP, Thio B, Cooper C, et al. Use of antidepressants and the risk of fracture of the hip or femur. Osteoporosis International. 2009;**20**:1705e13

[109] Moura C, Bernatsky S, Abrahamowicz M, Papaioannou A, Bessette L, Adachi J, et al. Antidepressant use and 10-year incident fracture risk: The population based Canadian multicentre osteoporosis study (CaMoS). Osteoporosis International. 2014;**25**(5):1473-1481. DOI: 10.1007/ s00198-014-2649-x PMID 24566587

[110] Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Archives of Internal Medicine. 2007;**167**(12):1246- 1251. DOI: 10.1001/archinte.167.12.1246 PMID 17592097

[111] Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. British Journal of Pharmacology. 2004;**141**(8):1285-1293. DOI: 10.1038/sj.bjp.0705762 PMID 15100164

[112] Abid S, Houssaini A, Chevarin C, Marcos E, Tissot CM, Gary-Bobo G, et al. Inhibition of gut- and lungderived serotonin attenuates pulmonary hypertension in mice. American Journal of Physiology. Lung Cellular and Molecular Physiology. 2012;**303**(6):L500-L508. DOI: 10.1152/ ajplung.00049.2012 PMID 22797248

[113] Jedlitschky G, Greinacher A, Kroemer HK. Transporters in human platelets: Physiologic function and impact for pharmacotherapy. Blood. 2012;**119**(15):3394-3402. DOI: 10.1182/ blood-2011-09-336933 PMID 22337717

[114] Ducy P, Karsenty G. The two faces of serotonin in bone biology. The Journal of Cell Biology. 2010;**191**(1):7.e13. DOI: 10.1083/jcb.201006123 PMID 20921133

[115] Oury F, Yadav VK, Wang Y, Zhou B, Liu XS, Guo XE, et al. CREB mediates

brain serotonin regulation of bone mass through its expression in ventromedial hypothalamic neurons. Genes Dev. 2010;**24**(20):2330-2342. DOI: 10.1101/ gad.1977210 PMID 20952540

[116] Li F, Chong ZZ, Maiese K. Vital elements of the Wnt-frizzled signaling pathway in the nervous system. Current Neurovascular Research. 2005;**2**(4):331- 340. DOI: 10.2174/156720205774322557 PMID 16181124

[117] Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008;**135**(5):825-837. DOI: 10.1016/j.cell.2008.09.059 PMID 19041748

[118] Deepa M, Grace M, Binukumar B, Pradeepa R, Roopa S, Khan HM, et al. High burden of prediabetes and diabetes in three large cities in South Asia: The center for cardio-metabolic risk reduction in South Asia (CARRS) study. Diabetes Research and Clinical Practice. 2015;**110**(2):172.e82. DOI: 10.1016/j. diabres.2015.09.005 PMID 26432412

[119] Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL, et al. Mechanisms of diabetes mellitusinduced bone fragility. Nature Reviews. Endocrinology. 2017;**13**(4):208-219. DOI: 10.1038/nrendo.2016.153 PMID 27658727

[120] Ferrari SL, Abrahamsen B, Napoli N, Akesson K, Chandran M, Eastell R, et al. Diagnosis and management of bone fragility in diabetes: An emerging challenge. Osteoporosis International. 2018;**29**(12):2585-2596. DOI: 10.1007/ s00198-018-4650-2 PMID 30066131

[121] Wang H, Ba Y, Xing Q, Du JL. Diabetes mellitus and the risk of fractures at specific sites:

A meta-analysis. BMJ Open. 2019;**9**(1):e024067. DOI: 10.1136/ bmjopen-2018-024067 PMID 30610024

[122] Bouillon R. Diabetic bone disease. Calcified Tissue International. 1991;**49**:155.e60. DOI: 10.1007/ BF02556109

[123] Murray CE, Coleman CM. Impact of diabetes mellitus on bone health. International Journal of Molecular Sciences. 2019;**20**(19). DOI: 10.3390/ ijms20194873 PMID 31575077

[124] Gilbert L, He X, Farmer P, Boden S, Kozlowski M, Rubin J, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology. 2000;**141**(11):3956-3964. DOI: 10.1210/ endo.141.11.7739 PMID 11089525

[125] Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death and Differentiation. 2003;**10**(10):1165- 1177. DOI: 10.1038/sj.cdd.4401285 PMID 14502240

[126] Sihota P, Yadav RN, Poleboina S, Mehandia V, Bhadada SK, Tikoo K, et al. Development of HFD-fed/low-dose STZtreated female Sprague-Dawley rat model to investigate diabetic bone fragility at different organization levels. JBMR Plus. 2020;**4**(10):e10379. DOI: 10.1002/ jbm4.10379 PMID 33103024

[127] Cipriani C, Colangelo L, Santori R, Renella M, Mastrantonio M, Minisola S, et al. The interplay between bone and glucose metabolism. Frontiers in Endocrinology. 2020;**11**:122. DOI: 10.3389/ fendo.2020.00122 PMID 32265831

[128] Tanaka K, Yamaguchi T, Kanazawa I, Sugimoto T. Effects of high glucose and advanced glycation end

*Non-GCs Drug-Induced Osteoporosis DOI: http://dx.doi.org/10.5772/intechopen.108296*

products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells. Biochemical and Biophysical Research Communications. 2015;**461**(2):193-199. DOI: 10.1016/j.bbrc.2015.02.091 PMID 25721666

[129] Sanz C, Vazquez P, Blazquez C, Barrio PA, Alvarez MDM, Blazquez E. Signaling VaL and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow. American Journal of Physiology. Endocrinology and Metabolism. 2010;**298**:E634e43. DOI: 10.1152/ ajpendo.00460.2009

[130] Shockley KR, Lazarenko OP, Czernik PJ, Rosen CJ, Churchill GA, Lecka-Czernik B. PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. Journal of Cellular Biochemistry. 2009;**106**(2):232-246. DOI: 10.1002/ jcb.21994 PMID 19115254

[131] Schwartz AV. Diabetes mellitus: Does it affect bone? Calcified Tissue International. 2003;**73**(6):515-519. DOI: 10.1007/s00223-003-0023-7 PMID 14517715

[132] Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, et al. Rosiglitazone-associated fractures in type 2 diabetes: An analysis from a diabetes outcome progression trial (ADOPT). Diabetes Care. 2008;**31**(5):845-851. DOI: 10.2337/dc07- 2270 PMID 18223031

[133] Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: A metaanalysis. Canadian Medical Association Journal. 2009;**180**(1):32-39. DOI: 10.1503/cmaj.080486 PMID 19073651

[134] Zhu ZN, Jiang YF, Ding T. Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials. Bone. 2014;**68**:115-123. DOI: 10.1016/j.bone.2014.08.010 PMID 25173606

[135] Mancini T, Mazziotti G, Doga M, Carpinteri R, Simetovic N, Vescovi PP, et al. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone. 2009;**45**(4):784-788. DOI: 10.1016/j.bone.2009.06.006 PMID 19527806

[136] Schwartz AV, Chen H, Ambrosius WT, Sood A, Josse RG, Bonds DE, et al. Effects of TZD use and discontinuation on fracture rates in Accord bone study. The Journal of Clinical Endocrinology and Metabolism. 2015;**100**(11):4059-4066. DOI: 10.1210/ jc.2015-1215 PMID 26305617
